TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01613677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT01404780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope (GVL)
Description: The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Direct Laryngoscope (MDL)
Description: Current standard of care at UHN for 50 years
Study: NCT03701672

Intervention type: OTHER
Intervention: Opioid Analgesic Treatment
Description: Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
Study: NCT04168229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mermaid 9 ITE
Description: A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mermaid 9 BTE
Description: A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
Study: NCT00237497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
Study: NCT04717323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: Gait with no pelvic assistance
Study: NCT00619658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone follow-up
Description: subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
Study: NCT01226992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral
Study: NCT02458794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu-Aura GainTM
Study: NCT01129375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00237497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Description: Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
Study: NCT01226992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Transplant
Description: Fecal slurry 50 grams stool in 500ml normal saline
Study: NCT00554268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-05204
Description: Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
Study: NCT03143933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: I.V propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: I.V propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT01821508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Treatment
Description: metabolic surgery for diabetes and weight control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-En-Y gastric bypass surgery
Description: laparoscopic surgical procedure with Endoscopic Surgical Stapler
Study: NCT03361566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake
Study: NCT00237497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets, orally, once daily for up to 28 nights.
Study: NCT03361566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake
Study: NCT04281849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAMS-HF Program
Description: BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully.
Study: NCT00718809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study: NCT01855607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical menthol
Description: 7.5% Methylsalicylate / 2% Menthol Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo lotion
Description: The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
Study: NCT01578109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo BMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT02430155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri balloon
Description: is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condom loaded foley's catheter
Description: Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
Study: NCT04619758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient (sunflower oil)
Description: In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
Study: NCT02181075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox® (LTLD)
Description: ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox® (LTLD)
Description: ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound of Target Liver Tumour
Description: Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound of Target Liver Tumour
Description: Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-LTLD Biopsy of Target Liver Tumour

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-LTLD Biopsy of Target Liver Tumour

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermometry of Target Tumour
Description: A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
Study: NCT03509766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Histamine skin testing
Description: skin testing using histamine
Study: NCT02921646

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of resting energetic expenditure
Description: measure of resting energetic expenditure
Study: NCT01406327

Intervention type: DRUG
Intervention: Ambrisentan
Description: Ambrisentan
Study: NCT01519635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
Study: NCT03179488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal TENS
Description: Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study: NCT04237831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Specified Dose on Specified Days
Study: NCT02689505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Study: NCT00219362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one injection of vCP1452 at W0, W4, W8 and W20

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one injection of vCP1452 at W4, W8 and W20

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20
Study: NCT01966458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare® VAS (HVAD)
Description: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control LVAD
Description: Any FDA-approved LVAD for destination therapy.
Study: NCT03194165

Intervention type: BIOLOGICAL
Intervention: Dolutegravir
Description: Dosage

Intervention type: BIOLOGICAL
Intervention: Raltegravir
Description: Dosage

Intervention type: BIOLOGICAL
Intervention: Rilpivirine
Description: Dosage

Intervention type: BIOLOGICAL
Intervention: Nevirapine
Description: Dosage

Intervention type: BIOLOGICAL
Intervention: Atazanavir
Description: Dosage

Intervention type: BIOLOGICAL
Intervention: Darunavir
Description: Dosage

Intervention type: BIOLOGICAL
Intervention: Ritonavir
Description: Dosage
Study: NCT01133912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, gemcitabine, lapatinib
Description: Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
Study: NCT02704988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carnoy Solution
Description: The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carnoy Solution
Description: The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GEWF Solution
Description: The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GEWF Solution
Description: The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
Study: NCT03592082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subsalicylate
Description: BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard antibiotic therapy
Description: antibiotic therapy administered per standard protocol
Study: NCT02268214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets
Study: NCT04664322

Intervention type: DEVICE
Intervention: non invasive ventilation and high flow nasal canulae oxygen therapy
Description: patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy

Intervention type: DEVICE
Intervention: non invasive ventilation and high flow nasal canulae oxygen therapy
Description: patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
Study: NCT03286153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ideal Body Weight First
Description: Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: \[50kg + (2.3kg\*every inch over 5 feet)\].

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Body Weight First
Description: Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
Study: NCT01755533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rural curriculum
Description: Students in schools randomly assigned to this condition receive the rural version of the curriculum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic curriculum
Description: Students in schools randomly assigned to this condition receive the classic version of the curriculum.
Study: NCT01366820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% Injection
Study: NCT06165276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Group C-CRM197 Conjugate Vaccine
Description: Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
Study: NCT01409447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic osteochondral composite
Description: We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
Study: NCT04829149

Intervention type: OTHER
Intervention: Observational
Description: Statin therapy group and Rosuzet tablet group

Intervention type: OTHER
Intervention: Observational
Description: Statin therapy group and Rosuzet tablet group
Study: NCT01745367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib Hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02268214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dapagliflozin
Description: Tablets
Study: NCT02165930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
Study: NCT00501202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369 (carisbamate)
Description: 200 mg tablet twice daily for 4 weeks
Study: NCT02694315

Intervention type: OTHER
Intervention: Bishop score
Description: calculation of modified Bishop score in numbers by digital vaginal examination

Intervention type: OTHER
Intervention: cervical length
Description: measuring cervical length by trans-vaginal ultrasound